Please login to the form below

Not currently logged in
Email:
Password:

Orphan Drug

Sponsored by

Finalist

Osteosarcoma - rewriting the rule book

Takeda UK in association with Liberation Communications


Summary of work

Mepact (mifamurtide), the first therapeutic advance for more than 20 years, has been developed for osteosarcoma, a very rare form of bone cancer. It is a highly aggressive cancer with a propensity to metastasise, affecting around 150 children and young adults each year across the UK. 

Before Mepact was available a third of all children and young adults diagnosed with osteosarcoma did not survive. With Mepact it is estimated that an additional 12 children across the UK will survive osteosarcoma each year and go on to live ‘normal’ long lives. Mepact was submitted to NICE for a technical appraisal and despite a Patient Access Scheme (PAS) being proposed by Takeda, both NICE and the SMC gave initial negative decisions in July 2010. 

Takeda worked with the Department of Health, NICE and the SMC to find a solution. After three further appraisal committee meetings, NICE acknowledged that to accurately assess the health economic value of Mepact, it would need to change its methodology to assess medicines that improve survival rates beyond 30 years. 

Following a fifth appraisal committee meeting a positive decision about the use of Mepact was given. The SMC also reversed its initial negative decision to recommend that Mepact could also be prescribed in Scotland. 

 

 

Executive summary as submitted


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics